Partnering Activity Update February 2, 2018
Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner 2010 KYPROLIS / Carfilzomib Multiple Myeloma / Proteasome inhibitor Amgen, USA (Onyx, USA) 2011 Ivabradine / -1162 Chronic Heart Failure / If channel blocker III / L Servier, France 2011 PARSABIV / Etelcalcetide Secondary Hyperparathyroidism / Calcium sensing receptor agonist Amgen, USA (KAI, USA) 2011 ORENCIA / Abatacept Rheumatoid Arthritis / T cell activation Inhibitor IV: SC: BMS, USA (co-development & co-marketing) Apr 2013 Opicapone / -2370 Symptom Reemergence in Parkinson s disease / COMT inhibitor II / L Bial, Portugal Oct 2013 Metyrosine / -5371 Pheochromocytoma / Tyrosine hydroxylase inhibitor I/II / L Valeant, USA Dec 2013 FORXIGA / Dapagliflozin Type 2 Diabetes / SGLT-2 inhibitor AstraZeneca, UK (co-promotion)
Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner May 2016 IT1208 Solid Tumors / Anti-CD4 mab I / - IDAC Theranostics, Japan (Exclusive evaluation and license negotiation right) Jul 2016 NKR-2 Solid Tumors and Hematological Malignancies / Allogeneic CAR T-cell therapy PC / PC Celyad, Belgium May 2017 Binimetinib / -7703 Encorafenib / -7702 Binimetinib / -7703 Encorafenib / -7702 BRAF-mutant melanoma / MEK inhibitor Combination BRAF inhibitor therapy BRAF-mutant melanoma / MEK inhibitor Combination BRAF inhibitor therapy III / Filed - / III Array, USA Aug 2017 SI-613 / -5704 Osteoarthritis / Combined drug of hyaluronic acid and NSAID III / - Seikagaku, Japan (co-development & marketing collaboration ) Oct 2017 Selinexor KPT-8602 Solid Tumors and Hematological Malignancies / XPO1 (Exportin 1) inhibitor Solid Tumors and Hematological Malignancies / second generationxpo1 (Exportin 1) inhibitor -/ Ⅲ - / PC Karyopharm, USA
Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner 2011 OPDIVO / Nivolumab Melanoma, NSCLC, RCC, Hodgkin Lymphoma, H&N Cancer, Gastric Cancer, etc. / Anti-PD-1 mab BMS, USA (out-license except JP, KR & TW) Jul 2014 OPALMON / Limaprost α-cd Lumber Spinal Canal Stenosis / oral PGE1 analogue L / Filed Meiji Seika Pharma, Japan (out-license in Thailand & Indonesia) Dec 2014 Tirabrutinib / -4059 B Cell Lymphoma / Btk inhibitor I/II / II Gilead Sciences, USA (out-license except JP, KR, TW, CN & ASEAN) Mar 2015 OPALMON / Limaprost α-cd Lumber Spinal Canal Stenosis / oral PGE1 analogue L / - China Chemical & Pharmaceutical, Taiwan (out-license in Taiwan) Mar 2016 etaprost / -9054 Glaucoma and Ocular Hypertension / FP/EP3 dual receptor agonist II / II Santen Pharmaceutical, Japan (out-license globally as ophthalmologic topical formulation) Dec 2017-4578 Solid Tumors / Prostaglandin Receptor (EP 4 ) Antagonist I / - BMS, USA (out-license except JP, KR, TW, CN & ASEAN) OPDIVO / Nivolumab Melanoma, NSCLC, RCC, Hodgkin Lymphoma, H&N Cancer, Gastric Cancer, etc. / Anti-PD-1 mab Jul 2014-4578 YERVOY / Ipilimumab Lirilumab / -4483 Urelumab / -4481 Relatlimab / -4482 BMS-986207 / -4686 Cabiralizumab / -4687 BMS-986205 / -7701 Solid Tumors / Prostaglandin Receptor (EP 4 ) Antagonist Melanoma, etc. / Anti-CTLA-4 mab Solid Cancer / Anti-KIR mab Solid Tumors / Anti-CD137 mab Melanoma / Anti-LAG3 mab Solid Tumors / Anti-TIGIT mab Solid /Blood cancer / Anti-CSF1R mab Melanoma/ IDO1 inhibitor I / - I / I/II I / I/II I/II / - I/II / I/II I / I III / III BMS, USA co-development & co-promotion in JP, KR & TW Launched in Japan
Collaboration with BMS for OPDIVO Innovative Immuno-oncology Therapy Start collaboration in May 2005 Expand collaboration in 2011 IP on PD-1 UltiMab Human Antibody Development System Worldwide except N America Medarex BMS Acquisition of Medarex in July 2009 North America JP, KR & TW BMS Worldwide except N America, JP, KR & TW North America
Strategic Alliance with BMS in JP, KR & TW To Strengthen Immuno-oncology Portfolio To Accelerate Combination Therapies Co-development Co-promotion Asset OPDIVO MEK inhibitor EP 4 Antagonist Development cost share Profit/loss allocation Mainly BMS BMS Asset Distribution Promotion BMS Subsidiary Medical sites BMS BMS BMS Asset Partly Asset Asset + Asset Equally Partly BMS Asset BMS Asset + BMS Asset BMS Asset BMS Subsidiary BMS BMS BMS Mainly Mainly Partly Equally Partly Mainly
Collaboration with BMS for ORENCIA Novel Biologic Inhibiting Upstream Inflammation in RA BMS Distribution SC SC IV BMSKK IV Promotion Medical sites SC IV BMSKK BMKK: Bristol-Myers Squibb K. K.
Collaboration with AstraZeneca for FORXIGA The First SGLT-2 Inhibitor in the World for Type 2 Diabetes Distribution Promotion Medical sites AZKK AZKK: AstraZeneca K.K.